Loading news...
LISTING LINK: https://www.premiersothebysrealty.com/single-family/mfr/a4681242/6610-gulf-of-mexico-drive-longboat-key-fl-34228 DROPBOX: https://tours.coastalhomephotography.net/public/vtour/display/2359971?idx=1#!/nav/gallery PHOTO CREDIT: Coastal Home Photography LONGBOAT KEY, Fla.
Fifth Third Bancorp lowered its stake in shares of Abbott Laboratories (NYSE: ABT) by 0.8% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,315,759 shares of the healthcare product maker's stock after selling 10,616 shares during the quarter. Fifth Third Bancorp
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profitability) and short-term price momentum-oriented stocks outperformed. Exact Sciences Corporation received a buyout offer in the fourth quarter by Abbott Laboratories (ABT) for a price of $105 in cash.
Cidel Asset Management Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 2.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 335,841 shares of the healthcare product maker's stock after buying an additional 6,660 shares during
Exploring the Strategic Moves of a Seasoned Value Investor Robert Bruce (Trades, Portfolio) recently submitted the 13F filing for the fourth quarter of 2025, p
Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from the prior quarterly rate.
Caisse Des Depots ET Consignations raised its stake in Abbott Laboratories (NYSE: ABT) by 61.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,560 shares of the healthcare product maker's stock after acquiring an additional 9,374 shares during the quarter.
This company has delivered earnings and dividend growth over time. Abbott's innovation and a new acquisition could spur more growth in the years to come.
Atria Investments Inc lowered its stake in shares of Abbott Laboratories (NYSE: ABT) by 6.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 171,968 shares of the healthcare product maker's stock after selling 12,301 shares during the period. Atria
Rockland Trust Co. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 26.8% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 110,519 shares of the healthcare product maker's stock after purchasing an additional 23,359 shares during the period. Rockland
S&CO Inc. trimmed its stake in Abbott Laboratories (NYSE: ABT) by 6.9% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 227,973 shares of the healthcare product maker's stock after selling 16,992 shares during the period. Abbott Laboratories comprises about 1.9%
Glucose Health (OTCMKTS:GLUC - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Risk and Volatility Glucose Health has a beta
Insight into Diamond Hill Capital (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Diamond Hill Capital (Trades, Portfolio) recently submitted its 13F fili
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Positive 12-month results from the VOLT-AF IDE Study presented at the AF Symposium and simultaneously published in JACC: Clinical Electrophysiology, reinforce the Volt™ Pulsed Field Ablation (PFA) System's industry-leading success rate for treating AFib1 New data from the FOCALFLEX CE Mark trial demonstrate the safety and efficacy of the TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, to significantly reduce AFib episodes for complex cases2 ABBOTT PARK, Ill., Feb. 6, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced new clinical data from two late-breaking presentations at AF Symposium in Boston (February 5-7, 2026) that demonstrate the strong safety and efficacy of the company's minimally invasive therapies to treat people with atrial fibrillation (AFib).
Abbott Laboratories (NYSE: ABT - Get Free Report) and American Bio Medica (OTCMKTS:ABMC - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Profitability This table compares Abbott Laboratories and
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and ranks 55th on the Fortune 500 list of the largest U.S.
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued stocks?
Abbott Labs' fourth-quarter report was disappointing, partly due to slow sales growth. But some promising new areas and a recent acquisition could help it on that front.